Analysis provides key questions – and answers – regarding future of JAK inhibitors for RA

MAUI, HAWAII – Now is a good time to assess the future of the Janus kinase inhibitor class of oral small-molecule medications for rheumatoid arthritis based on new evidence that addresses many of the...
Source: Rheumatology News - Category: Rheumatology Source Type: research